Natco Pharma Ltd.
Snapshot View

1006.30 -9.75 ▼-1.0%

30 July 2021, 09:54:00 A.M.
Volume: 2,027

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.natcopharma.co.in
Financial Indicators
Market Cap 18,526.43 Cr.
Earnings per share (EPS) 24.18 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 42.02 Trailing Twelve Months Ending 2021-03
Industry PE 34.39 Trailing Twelve Months Ending 2021-03
Book Value / Share 226.04 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.49 Calculated using Price: 1,016.05
Dividend Yield 0.66 Period Ending 2020-03
No. of Shares Subscribed 18.23 Cr. 182,337,825 Shares
FaceValue 2
Company Profile

Natco Pharma was promoted by V C Nannapaneni in the year 1981 as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh. The company focus is primarily on niche therapeutic areas and complex products. It market and distribute products in various countries. It also operates in certain key geographies through its subsidiaries.

Natco Pharma manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets. In the API segment, company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.

Business area of the company

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). It is also engaged in contract manufacturing business, whereby it undertake selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry.

Products:

  • Formulations
  • API’s
  • Contract manufacturing
  • Crop Health Sciences

Milestone:

  • 1981: Incorporated Natco Pharma Division at Kothur, Mahaboobnagar Dist, Telangana, India.
  • 1984: First full year in operation- sales of Rs 0.5 million
  • 1986: Inaugurated parental manufacturing facility at Nagarjunasagar, Telangana, India.
  • 1993: Inaugurated Natco’s chemical division at Mekaguda in Telangana.
  • 1995: Natco trust was founded. Natco merged three of groups companies with the parent company.
  • 1997: Inaugurated Natco Research Center (NRC) at Sanathnagar, Hyderabad, India.
  • 2003: Launched Oncology division with introduction of the flagship brand VEENAT (generic Imatinib Mesylate) for the treatment of chronic myelogenous leukemia.
  • 2006: Incorporated a finished dosage facility at Dehradun, Uttrakhand.
  • 2007: Natco launched its first ever ANDA in the US market. Natco acquired Savemart Pharmacy in USA.
  • 2008: Natco filed its first paragraph IV filing in the US market.
  • 2009: Inaugurated Natco Organics at Chennai, India with facilities dedicated for Cyto-toxic APIS’s Biotechnology products. Natco’s turnover reached $100 million.
  • 2011: Incorporated Natcofarma do Brazil LTDA.
  • 2012: Compulsory License was granted by government of India for patent protected anti-cancer drug Nexavar of Bayer.
  • 2012: Established Natco Pharma Asia Pte Ltd for sales and distribution in Singapore and winner of Golden peacock award for CSR work.
  • 2013: Established Natco Pharma Canada Inc for sales and distribution in Canada.
  • 2014: Established Natco Pharma Australia Pty Ltd for sales and distribution in Australia.
  • 2016: Sold U.S. based Save Mart pharmacy store. 
  • 2016: Winner of 'Golden Peacock Environment Management Award' for the Year 2016.
  • 2016: Launched generic version of Oseltamivir Phosphate capsules in the United States.
  • 2017: Started Cardiology and Diabetology divisions for domestic market with launches like Dabigatran. 
  • 2017: Launched Glatiramer Acetate injection (20 & 40 mg/ml) in the US. 
  • 2017: Launched complex drug delivery product, liposomal doxorubicin in the US.
  • 2018: USFDA completed inspection of Natco’s Mekaguda API facility with zero observations. 
  • 2018: Natco launched its first generic version of oral tablets Teriflunomide for Multiple Sclerosis in India. 
  • 2018: Natco introduced generic Posaconazole injection, available for the first time in India.
  • 2019: Commercial manufacturing operations begin in NATCO's Visakhapatnam Formulation Facility. 
  • 2019: Natco launches Crop Health Sciences Division.
  • 2019: Natco Pharma invests Rs 5 crore in OMRV Hospitals.
  • 2019: Natco Pharma has commenced commercial operations at Finished Dosage Formulations (FDF) facility in Visakhapatnam.
  • 2020: Natco Pharma’s subsidiary -- Natco Pharma (Canada) Inc., has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada. The terms of the agreement are confidential as per the agreement.
  • 2020: Natco Pharma has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag) Andhra Pradesh, India.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.96%
1 Week
-7.81%
1 Month
-10.86%
3 Month
+12.23%
6 Month
+12.73%
1 Year
+34.34%
2 Year
+92.93%
5 Year
+59.97%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 14.16 13.08 15.58 16.57 14.62 33.21 29.70 19.75 12.71
Return on Capital Employed (%) 15.72 16.04 18.02 15.62 18.04 39.21 35.28 23.71 14.82
Return on Assets (%) 7.25 6.64 8.62 10.10 9.72 23.43 23.05 16.02 10.30

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 474 534 726 846 1,296 1,649 3,072 3,489 3,774
Non Curr. Liab. 171 191 151 119 28 38 47 83 118
Curr. Liab. 259 345 312 414 493 627 592 729 685
Minority Int. 1 11 7 5 5 4 4 2 11
Equity & Liab. 905 1,080 1,196 1,384 1,822 2,318 3,715 4,303 4,588
Non Curr. Assets 612 750 828 901 985 1,230 1,584 1,956 2,262
Curr. Assets 293 330 368 483 837 1,087 2,131 2,347 2,326
Misc. Exp. not W/O
Total Assets 905 1,080 1,196 1,384 1,822 2,318 3,715 4,303 4,588

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 524 661 739 825 1,141 2,020 2,185 2,095 1,915
Other Income 9 12 17 15 10 14 40 130 107
Total Income 533 673 756 840 1,151 2,034 2,225 2,225 2,022
Total Expenditure -414 -511 -560 -612 -869 -1,337 -1,256 -1,300 -1,332
PBIDT 118 162 196 228 283 697 969 925 690
Interest -23 -26 -37 -32 -23 -19 -15 -19 -22
Depreciation -16 -22 -30 -47 -51 -54 -66 -81 -100
Taxation -21 -36 -31 -4 -53 -140 -192 -182 -111
Exceptional Items -12 -15
PAT 58 66 98 130 156 485 695 642 458

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 65 61 144 93 112 346 464 669 417
Cash Fr. Inv. -127 -107 -109 -115 -176 -299 -1,116 -612 -167
Cash Fr. Finan. 63 26 -35 29 154 -48 651 -51 -251
Net Change 1 -20 0 7 91 -1 -1 6 -1
Cash & Cash Eqvt 35 10 10 12 -74 24 22 28 20

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 49.01 48.98 48.98 48.93 48.93 48.91 48.91 48.87 48.87
Public 50.99 51.02 51.02 51.07 51.07 51.09 51.09 51.13 51.13
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 28 Jul 2021
Clarification / Confirmation On News Item Appearing In 'Media / Publication'
With reference to the above subject we wish to inform you that we had given a press release as legal update on 7th July 2021
We further clarify that the news article timesofindia.indiatimes.com dated July 26 2021 captioned HC restrains Natco Pharma from manufacturing using insecticides with FMC Corporations patent pertaining the press release made by the company on 7th July 2021
Tue, 27 Jul 2021
Clarification sought from Natco Pharma Ltd
The Exchange has sought clarification from Natco Pharma Ltd with respect to news article appearing on https://timesofindia.indiatimes.com July 26 2021 titled "HC restrains Natco from using insecticides with FMC Corps patent".

The reply is awaited.
Mon, 12 Jul 2021
Announcement under Regulation 30 (LODR)-Investor Presentation
Q4 Investor presentation for the FY 2020-21

Technical Scans View Details

Thu, 29 Jul 2021
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Closing Near 100 EMA Closing Near 100 EMA
Close Crossing Lower Bollinger Band From Below Close Crossing Lower Bollinger Band From Below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 707.05 +0.5%
Divi's Laboratories Ltd. 128,656.69 4,891.95 +0.9%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,745.90 +1.6%
Cipla Ltd. 71,170.06 882.40 +0.0%
Cadila Healthcare Ltd. 58,547.84 578.60 +1.2%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,064.15 +0.6%
Aurobindo Pharma Ltd. 53,214.94 909.70 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 707.05 +0.5%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,891.95 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,745.90 +1.6%
Cipla Ltd. Consolidated 2021-03 29.59 882.40 +0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 578.60 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,064.15 +0.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 909.70 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 707.05 +0.5%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,891.95 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,745.90 +1.6%
Cipla Ltd. Consolidated 2021-03 3.88 882.40 +0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 578.60 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,064.15 +0.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 909.70 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 707.05 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,891.95 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,745.90 +1.6%
Cipla Ltd. Consolidated 2020-03 0.18 882.40 +0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 578.60 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,064.15 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 909.70 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 707.05 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,891.95 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,745.90 +1.6%
Cipla Ltd. Consolidated 2020-03 10.09 882.40 +0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 578.60 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,064.15 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 909.70 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 707.05 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,891.95 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,745.90 +1.6%
Cipla Ltd. Consolidated 2020-03 12.53 882.40 +0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 578.60 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,064.15 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 909.70 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 707.05 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,891.95 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,745.90 +1.6%
Cipla Ltd. Consolidated 2020-03 17,131.99 882.40 +0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 578.60 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,064.15 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 909.70 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 707.05 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,891.95 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,745.90 +1.6%
Cipla Ltd. Consolidated 2020-03 1,546.98 882.40 +0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 578.60 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,064.15 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 909.70 +0.2%